Tilksew A. Tedla

Tilksew Tedla practices at Bakersfield Surgical Center in Bakersfield, California.

Tilksew Tedla's NPI, 1356856132, was assigned on December 3, 2017. Tilksew Tedla holds Georgia license RN274800.

Tilksew Tedla's primary practice is Bakersfield Surgical Center, at 3550 Q St, Bakersfield, CA 93301 in Kern County. The practice phone is (661) 388-4143.

Tilksew Tedla's primary practice is Bakersfield Surgical Center in Bakersfield, California. Tilksew Tedla is also affiliated with John C. Fremont Healthcare District. The medical group on file is Pain Clinics of Central California. Dmand AI also links Tilksew Tedla to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Tilksew Tedla practices, 2 sites in all. Vendor and product names are available with a free account.

Nurse practitioner is Tilksew Tedla's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Dmand AI has Tilksew Tedla's licenses on file in 2 states: Georgia and Texas.

Dmand AI lists arthritis, fibromyalgia and chronic pain, joint pain, lower back pain, mobility impairment, multiple sclerosis, muscle pain, fibromyalgia, and limb pain and neck pain and spine problems among the conditions Tilksew Tedla treats.

CMS data shows 3,443 Medicare services from Tilksew Tedla across 11 procedure codes in 2024, for 387 Medicare patients. Medicare paid $145,770 for them. Every service was in an office.

CMS counts 387 Medicare patients who saw Tilksew Tedla in 2024. The largest group is 65 to 74, with 187 patients. 75% of them have arthritis, and 75% have high blood pressure. 91% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Tilksew Tedla's median patient age at 62, with 63% women.

In 2024, Tilksew Tedla wrote 3,656 Medicare Part D claims for 496 patients. 93% of them were for generic drugs. CMS names the drug for 3,599 of them, across 23 drugs with 11 or more claims each, at $185,069 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 24 out of 100 for Tilksew Tedla for performance year 2024, reported individually. Tilksew Tedla accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Tilksew Tedla as offering telehealth.

CMS Open Payments shows 35 general payments to Tilksew Tedla from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Bausch Health Americas, Inc. paid the most, $534.